Abstract
During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
Keywords: COVID-19; Casirivimab; Imdevimab; Immunocompromised; Monoclonal antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, Neutralizing antibodies, Remdesivir, monoclonal antibodies, Casirivimab, Imdevimab, Immunocompromised, XLA., 【초록키워드】 Treatment, coronavirus disease, pandemic, monoclonal antibody, immunodeficiency, outcome, Case report, Patient, disease, chronic infection, humoral, therapeutic option, XLA, higher risk, X-linked, 【제목키워드】 neutralizing antibody, Remdesivir, Patient, X-linked,
【저자키워드】 COVID-19, SARS-CoV-2, Neutralizing antibodies, Remdesivir, monoclonal antibodies, Casirivimab, Imdevimab, Immunocompromised, XLA., 【초록키워드】 Treatment, coronavirus disease, pandemic, monoclonal antibody, immunodeficiency, outcome, Case report, Patient, disease, chronic infection, humoral, therapeutic option, XLA, higher risk, X-linked, 【제목키워드】 neutralizing antibody, Remdesivir, Patient, X-linked,
{{{ 추상적인 }}}
코로나바이러스 질병 2019(COVID-19) 대유행 기간 동안 체액성 면역결핍증 환자는 만성 감염이 발병할 위험이 더 높고 부정적인 결과를 초래할 수 있습니다. 이 모집단에 대한 치료 옵션에 대한 데이터는 거의 없습니다. 이 증례 보고서는 X-연관 무감마글로불린혈증이 있는 성인 환자에서 렘데시비르와 단클론항체를 사용한 질병 재발의 치료에 대해 논의합니다.
{{ 키워드: }} 코로나19; 카시리비맙; 임데비맙; 면역저하; 모노클로날 항체; 중화 항체; 렘데시비르; 사스 코로나바이러스 2; XLA.